Incidence of hypertensive response during endotracheal intubation between supplement intravenous bolus propofol and sevoflurane: A prospective randomized-controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220117005

Enrollment

Registered

2022-01-17

Start date

2021-01-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood pressure and heart rate after tracheal intubation Hypertensive response, Intubation, Propofol, Sevoflurane

Interventions

Inhale 2% sevoflurane,Bolus propofol 1 mg/kg

Experimental Drug,Experimental Drug

Sevoflurane,Propofol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Adult 18-65 years ASA physical status I-II

Exclusion criteria

Exclusion criteria: SBP baseline 30kg/m2 Anticipated difficult intubation Risk aspiration Patients with severe cardiovascular diseases Contraindication for propofol, fentanyl, cisatracurium and sevoflurence Abnormal EKG: bradycardia < 50 bpm, second to third degree AV block, LBBB, ST-T change that indicate MI

Design outcomes

Primary

Measure	Time frame
Incidence of hypertensive response after tracheal intubation 5 min after tracheal intubation Ratio	—

Secondary

Measure	Time frame
Blood pressure and heart rate pre-intubation 5 min after intubation Mean,Adverse effect and vasoactive agents used among pre- intubation and post-intubation 5 min after intubation Percentage	—

Countries

Thailand

Contacts

Public ContactPanusart Karaket

Faculty of Medicine, Khon Kaen university

Panusart@gmail.com0804605085

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026